Aims: In this study we introduce selected CTCs markers (VEGF, VEGFR, EGF and EGFR) utility in monitoring and rational selection of gynecological cancers cases (cervical, endometrial and ovarian) and their association with clinical parameters along with brief notes how they can help to elucidate the treatment outcomes. Methods: Expressions measured by flow cytometric methods as previously described by Iannone et al (2005). Briefly, the MNCs form 2 ml blood sample were harvested, fixed in 1% paraformaldehyde and permeabilised. Cells were incubated at 37 °C for 2 h with primary antibodies which followed by incubation with FITC-labeled secondary antibody for 60 min. Quantitative changes in expression of markers were analyzed as mean fluorescence intensity (MFI) at FL1-H (Log) axis using BD-LSR cytometer. Results: The cases with low expression level as well as positivity of selected CTCs markers mRNA were also showing low micro vessel density (MVD) count and most of them were from lower histopathological stage of disease .